Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJPS (3) Autor Cazarim,Maurílio de Souza (3) Pereira,Leonardo Régis Leira (3) Cruz-Cazarim,Estael Luzia Coelho da (2) Ayres,Lorena Rocha (1) Nunes,Altacílio Aparecido (1) Reis,Tiago Marques dos (1) Rodrigues,João Paulo Vilela (1) Mais... Palavra-chave Hypertension (2) Pharmaceutical services (2) Brazilian Public Health System (1) Costs and cost analysis (1) Diabetes Mellitus/treatment/cost-effectiveness/evaluation (1) Evidence-based medicine (1) Health Expenditures (1) Pharmaceutical care (1) Pharmaceutical economics (1) Primary health care (1) Prolonged Action Insulin (1) Review literature as topic (1) Short Action Insulin (1) Mais... Tipo do documento Info:eu-repo/semantics/article (3) Ano 2020 (1) 2017 (2) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil BJPS Cazarim,Maurílio de Souza; Nunes,Altacílio Aparecido; Pereira,Leonardo Régis Leira. ABSTRACT In Brazil, 80% of hypertensive patients have no blood pressure controlled, this fact has caused severe financial consequences for the public health system (PHS) and the Pharmaceutical Care (PC) has emerged as an effective alternative. The aim of this study was to analyze the costs and outcomes of systemic arterial hypertension (SAH) for conventional assistance compared to assistance with PC in the PHS. This is a pharmacoeconomic study with cost-consequence analysis nested to clinical trial. Hypertensives patients were followed-up from 2006 to 2012. During 2009 they were assisted by the PC program in Ribeirão Preto-SP, Brazil. Clinical indicators, systolic and diastolic blood pressure (SBP and DBP), triglycerides, total cholesterol (TC) and its... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pharmaceutical economics; Pharmaceutical services; Health Expenditures; Hypertension; Pharmaceutical care; Costs and cost analysis. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000300620 Systematic review protocol: following PRISMA guide from Cochrane to generate evidence as treatment effect of pharmaceutical care for hypertension in primary care BJPS Cazarim,Maurílio de Souza; Reis,Tiago Marques dos; Cruz-Cazarim,Estael Luzia Coelho da; Pereira,Leonardo Régis Leira. Pharmaceutical care (PC) is in the implementation process in Brazil and Latin America. Synthesis of evidence has been requested for monitoring and evaluating the process regarding the treatment effect. The objective is to build and disseminate a systematic review protocol to make a standard for updating results from pharmaceutical care for hypertension and for other diseases. This is a protocol for systematic review studies regarding a real example of a protocol reasoned in pharmaceutical care for hypertension in primary care. This protocol was delineated grounded in the Cochrane Handbook. Descriptors and words were defined using MeSH (Medical Subject Headings), DeCS (Descriptors in Health Sciences) and Emtree thesaurus, and the search was performed in... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pharmaceutical services; Hypertension; Primary health care; Review literature as topic; Evidence-based medicine. Ano: 2020 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100620 Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system BJPS Cazarim,Maurílio de Souza; Rodrigues,João Paulo Vilela; Cruz-Cazarim,Estael Luzia Coelho da; Ayres,Lorena Rocha; Pereira,Leonardo Régis Leira. ABSTRACT Human insulin is provided by the Brazilian Public Health System (BPHS) for the treatment of diabetes, however, legal proceedings to acquire insulin analogs have burdened the BPHS health system. The aim of this study was to perform a cost-effectiveness analysis to compare insulin analogs and human insulins. This is a pharmacoeconomic study of cost-effectiveness. The direct medical cost related to insulin extracted from the Ministry of Health drug price list was considered. The clinical results, i.e. reduction in glycated hemoglobin (HbA1c), were extracted by meta-analysis. Different scenarios were structured to measure the uncertainties regarding the costs and reduction in HbA1c. Decision tree was developed for sensitivity of Incremental Cost... Tipo: Info:eu-repo/semantics/article Palavras-chave: Diabetes Mellitus/treatment/cost-effectiveness/evaluation; Prolonged Action Insulin; Short Action Insulin; Brazilian Public Health System. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000300616 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco